Free Trial
OTCMKTS:ENZN

Enzon Pharmaceuticals 5/9/2025 Earnings Report

Enzon Pharmaceuticals logo
$0.08 0.00 (-3.53%)
As of 08/8/2025 03:58 PM Eastern

Enzon Pharmaceuticals EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Enzon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enzon Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Enzon Pharmaceuticals Earnings Headlines

Enzon Pharmaceuticals, Inc. (ENZN) - Yahoo Finance
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Enzon and Viskase Enter into Merger Agreement
See More Enzon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enzon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enzon Pharmaceuticals and other key companies, straight to your email.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals (OTCMKTS:ENZN), Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

View Enzon Pharmaceuticals Profile

More Earnings Resources from MarketBeat